Recombinant Fusion Proteins
"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
| Descriptor ID |
D011993
|
| MeSH Number(s) |
D12.776.828.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".
This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 8 | 9 |
| 1995 | 2 | 5 | 7 |
| 1996 | 0 | 12 | 12 |
| 1997 | 1 | 9 | 10 |
| 1998 | 1 | 12 | 13 |
| 1999 | 2 | 11 | 13 |
| 2000 | 0 | 16 | 16 |
| 2001 | 1 | 15 | 16 |
| 2002 | 2 | 14 | 16 |
| 2003 | 2 | 11 | 13 |
| 2004 | 4 | 16 | 20 |
| 2005 | 2 | 12 | 14 |
| 2006 | 3 | 6 | 9 |
| 2007 | 0 | 7 | 7 |
| 2008 | 5 | 8 | 13 |
| 2009 | 2 | 8 | 10 |
| 2010 | 5 | 9 | 14 |
| 2011 | 0 | 8 | 8 |
| 2012 | 4 | 6 | 10 |
| 2013 | 2 | 4 | 6 |
| 2014 | 4 | 8 | 12 |
| 2015 | 3 | 5 | 8 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 6 | 7 |
| 2018 | 1 | 3 | 4 |
| 2019 | 3 | 0 | 3 |
| 2020 | 1 | 2 | 3 |
| 2021 | 2 | 3 | 5 |
| 2022 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.
-
Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers. J Immunol. 2022 03 15; 208(6):1362-1370.
-
Complement Inhibition Alleviates Cholestatic Liver Injury Through Mediating Macrophage Infiltration and Function in Mice. Front Immunol. 2021; 12:785287.
-
Safety and Outcomes of Intravitreal Aflibercept in Diabetic Macular Edema - A Systematic Review. Curr Pharm Des. 2022; 28(21):1758-1768.
-
In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.
-
Chronic complement dysregulation drives neuroinflammation after traumatic brain injury: a transcriptomic study. Acta Neuropathol Commun. 2021 07 19; 9(1):126.
-
Natural immunoglobulin M-based delivery of a complement alternative pathway inhibitor in mouse models of retinal degeneration. Exp Eye Res. 2021 06; 207:108583.
-
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clin Cancer Res. 2021 06 15; 27(12):3339-3350.
-
Probing Interdomain Linkers and Protein Supertertiary Structure In Vitro and in Live Cells with Fluorescent Protein Resonance Energy Transfer. J Mol Biol. 2021 03 05; 433(5):166793.
-
C2 IgM Natural Antibody Enhances Inflammation and Its Use in the Recombinant Single Chain Antibody-Fused Complement Inhibitor C2-Crry to Target Therapeutics to Joints Attenuates Arthritis in Mice. Front Immunol. 2020; 11:575154.
-
Nascent mutant Huntingtin exon 1 chains do not stall on ribosomes during translation but aggregates do recruit machinery involved in ribosome quality control and RNA. PLoS One. 2020; 15(7):e0233583.